Entasis Therapeutics Holdings Inc. announced the appointment of David Altarac, M.D., MPA as Chief Medical Officer, effective November 4, 2019. In conjunction, Robin Isaacs, M.D., who has served as the company’s Chief Medical Officer since July 2015, announced his plans to retire at the end of 2019. Dr. Isaacs will continue as an advisor to the company as the Phase 3 programs move toward regulatory review. Dr. Altarac is an industry leader in R&D across multiple therapy areas and is recognized as a strategic biopharmaceutical leader. Over the course of a 20+ year career, he has led multiple new drug approvals in major global markets as well as many product extensions in global emerging and secondary markets. As Chief Medical Officer, Dr. Altarac will be responsible for leading clinical development for Entasis’ lead programs, sulbactam-durlobactam and zoliflodacin, both of which are undergoing global Phase 3 trials. In addition, he will lead Medical Affairs, Pharmacovigilance, Quality and Regulatory Affairs. Dr. Altarac will also lead the advancement of ETX0282CPDP clinical development and the expansion of the company’s pipeline of pathogen-targeted antimicrobials. Prior to joining Entasis, Dr. Altarac was Senior Vice President and Head of Global Regulatory Affairs, Global Drug Safety and R&D Quality and Compliance at Shire. Prior to joining Shire, Dr. Altarac spent two years as VP, Regulatory Affairs at NeoStem and more than 13 years at Merck & Company, where he served on multiple senior leadership teams and held roles of increasing responsibility.